Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA 3 study results on rilzabrutinib’s capability to treat the underlying immune dysregulation in ITP. An oral presentation reported rates of platelet response according to International Working Group (IWG) criteria—a major clinical endpoint for making treatment decisions. Two poster presentations reported the first efficacy and safety results from […]
Amino acids are the basic structural units of proteins, which are critical macromolecules of all living organisms. Proteins play a role in almost every aspect of biological function, and structure and function are conferred by the sequence and nature of amino acids. Read the detailed description of amino acids. Structure […]
AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in […]
The first stage of mitosis and meiosis, two crucial cellular division processes that support an organism’s growth, repair, and reproduction, is known as prophase.The specifics of what transpires and why differ depending on the cell’s activity in either mitosis or meiosis, even though chromosomal condensation and spindle construction are shared […]
